Loncastuximab tesirine

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023
Health, Pharmaceutical, Research, Antibody, Immune system, Non-Hodgkin lymphoma, Therapy, Lymphoid leukemia, Loncastuximab tesirine, Scleroderma, CRS, JW, IND, Tafasitamab, Tisagenlecleucel, B-cell lymphoma, Patient, Systemic scleroderma, CD19, Blinatumomab, FDA, Lupus, Acute leukemia, SLE, Chronic lymphocytic leukemia, Novartis, Sjögren syndrome, Neurotoxicity, Quality of life, NHL, Fast Track, ALL, Cytokine release syndrome, CLL, Vaccine, Pharmaceutical industry, Amgen

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

Retrieved on: 
Thursday, August 31, 2023
Lymphoma, Loncastuximab tesirine, Abstract, Polatuzumab vedotin, Society, Progression-free survival, Follicular lymphoma, Diffuse large B-cell lymphoma, DLBCL, Safety, SOHO, Doctor of Philosophy, B-cell lymphoma, Nanakaly Hospital for Hematology & Oncology, Mosunetuzumab, Dor, The Year's Best Science Fiction: Eleventh Annual Collection, ADC, Poster, Trial of the century, Therapy, NYSE, ORR, Medical device, Pharmaceutical industry, Fine chemical, Rituximab, MD, Patient

LAUSANNE, Switzerland, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023.

Key Points: 
  • For LOTIS-5, the Phase 3 study evaluating the combination of ZYNLONTA with rituximab, we are encouraged by the updated safety run-in results being presented at SOHO 2023.
  • It is the confirmatory trial for accelerated approval for 3L+ and would also support potential label expansion into 2L+ in combination with rituximab.
  • Dosing arms include ZYNLONTA (loncastuximab tesirine-lpyl) plus polatuzumab vedotin, as well as ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab and mosunetuzumab, t-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • Combining these agents with different mechanisms of action has the potential to have increased activity compared to either agent alone.

Global Rare Disease Therapeutics Market Report 2023: Players Include AbbVie, Novo Nordisk, Sanofi, Bayer, Amgen and Eisai - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 5, 2023
Biotechnology, Pharmaceutical, Health, Orphan Drug Act of 1983, CDER, COVID-19, Therapy, Disease, NORD, Bone marrow, DSM-IV codes, Pharmacy, Loncastuximab tesirine, Infection, National Organization for Rare Disorders, USD, Competition, Market, Malignancy, Administration, EURORDIS, Rare, Patient, Laboratory, European Organization for Quality, European, Center for Drug Evaluation and Research, Route of administration, Knowledge, Pharmaceutical Research and Manufacturers of America, Global Genes, D, Pharmaceutical industry, Research, Mobocertinib

The global rare disease therapeutics market is projected to undergo a vigorous expansion in the coming years.

Key Points: 
  • The global rare disease therapeutics market is projected to undergo a vigorous expansion in the coming years.
  • The market for treating rare diseases will expand as the number of rare diseases rises.
  • Therefore, continued market expansion prospects will arise from research into unmet rare disease treatments in the future.
  • According to clinicaltrials.gov, there are around 2,615 studies related to rare disease therapeutics which are in different phases of development across different parts of the globe.

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Retrieved on: 
Wednesday, December 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, EC, CHMP, Food, Therapy, Committee for Medicinal Products for Human Use, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Royal commission, DLBCL, Advanced Therapy Medicinal Product, Patient, Medical Affairs Bureau, NYSE, Development, Committee, ADC, European Commission, FDA, Mitsubishi Tanabe Pharma, B-cell lymphoma, European, Research and development, EMA, Marketing, Sutro Biopharma, Pharmaceutical industry, Medical device, Swedish Orphan Biovitrum, EU, Loncastuximab tesirine

ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • “This approval marks a major milestone in our pursuit to expand the global reach of ZYNLONTA,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
  • Under the terms of the agreement, the EC approval of ZYNLONTA triggers a $50 million milestone payment from Sobi to ADC Therapeutics.
  • Overland ADCT BioPharma is now conducting a registrational pivotal Phase 2 clinical trial of ZYNLONTA in relapsed or refractory DLBCL in China.

Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Retrieved on: 
Wednesday, December 21, 2022
NYSE, Food, Malignancy, Disease, PMC, Safety, EMA, PBD, US Foods, Patient, Research and development, Nasdaq Stockholm, B-cell lymphoma, Lymphoma, Marketing, Lymphoid leukemia, FDA, Diffuse large B-cell lymphoma, Development, EC, SEK, Genetics, Committee, Control, Lymphatic system, Cancer research, ADC, Enzyme, DNA, Therapy, Degenerative disease, Incidence, Distortion, Cancer, Cancer Research UK, European Commission, Induced cell cycle arrest, USD, European Commission–AstraZeneca COVID-19 vaccine dispute, DNA repair, Medical Affairs Bureau, Pharmaceutical industry, Fine chemical, San Francisco Bay Area, DLBCL, Swedish Orphan Biovitrum, EU, Loncastuximab tesirine

"We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."

Key Points: 
  • "We are thrilled that Zynlonta will be available to help fill a critical unmet need for patients with DLBCL across Europe."
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive and malignant disease in haematology with an incidence in Europe of approximately 8.8 cases per 100,000 adults per year1.
  • ADC Therapeutics' CD19-directed ADC Zynlonta (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.
  • Postal address SE-112 76 Stockholm, Sweden
    For details on how to contact the Sobi Investor Relations Team, please click here .

FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

Retrieved on: 
Monday, December 12, 2022
Heme, Therapy, DLBCL, Lymphatic system, Immune system, PBD, Society, Biomarker, Patient, Cancer, ADC, Research, Biology, NYSE, Diffuse large B-cell lymphoma, FDA, Molecular biology, Nucleic acid thermodynamics, Multimedia, Loncastuximab tesirine, Control, SAN, Blood, Machine learning, ASH, Hodgkin lymphoma, Medical imaging, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Catriona lonca, Camisole

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research.
  • "We look forward to further exploration of these findings to determine their significance for healthcare providers trying to identify the most appropriate treatments for patients with DLBCL."
  • "ADC Therapeutics is a leader in the field of antibody-drug conjugates," said Mike Nolan , chief executive officer, Freenome.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Scenic Biotech Appoints Jens Würthner as Chief Medical Officer

Retrieved on: 
Monday, October 24, 2022
Health, Technology, Other Technology, Software, Pharmaceutical, Biotechnology, National Institutes of Health, AstraZeneca, Therapy, Pharmacology, Lists of diseases, Laboratory, Patient, Biotechnology, Molecular Biology of the Cell, Publication, Technology, University, Oscar, University of Hamburg, National Cancer Institute, Doctor of Philosophy, MD, Health, Novartis, GlaxoSmithKline, National, CEO, ADC, King's College, CD47, Gene, List of life sciences, Loncastuximab tesirine, Pharmaceutical industry

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the appointment of Jens Wrthner, MD, PhD, as Chief Medical Officer.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced today the appointment of Jens Wrthner, MD, PhD, as Chief Medical Officer.
  • Dr. Wrthner brings Scenic Biotech 20 years of clinical development expertise.
  • I am excited to work alongside Oscar and everyone at Scenic Biotech as we advance a broad portfolio of disease-modifying therapeutics for the benefit of patients, added Dr. Jens Wrthner, Chief Medical Officer of Scenic Biotech.
  • By understanding the genomes power to correct toward health, Scenic Biotech will bring novel therapeutics to patients in need.

ADC Therapeutics SA Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Tuesday, September 20, 2022
ADC, GLOBE, Company, Loncastuximab tesirine, News, Review, NYSE, Morgan Stanley, Private investigator

​LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. ADC investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADC Therapeutics SA (ADC or the Company) (NYSE: ADCT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors.
  • ADC investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

Retrieved on: 
Wednesday, September 14, 2022
Professional Services, Class Action Lawsuit, ADC, Certification, Company, Ethics, News, Suite, Loncastuximab tesirine, NYSE, Morgan Stanley, Private investigator

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (ADC or the Company) (NYSE: ADCT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (ADC or the Company) (NYSE: ADCT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • ADC was the subject of a Morgan Stanley downgrade on September 9, 2022, from overweight to equal weight.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm

Retrieved on: 
Wednesday, September 14, 2022
Professional Services, Class Action Lawsuit, ADC, Certification, Company, Ethics, News, Suite, Loncastuximab tesirine, NYSE, Morgan Stanley, Private investigator

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (ADC or the Company) (NYSE: ADCT ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (ADC or the Company) (NYSE: ADCT ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • ADC was the subject of a Morgan Stanley downgrade on September 9, 2022, from overweight to equal weight.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.